Investigational drug · Phase 2
GB2064
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Myelofibrosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 3, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "GB2064"
First trial start
2021
Jun 9, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GB2064", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myelofibrosis
Approved drugs for the same conditions: Myelofibrosis · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "GB2064" as an intervention, largest first.
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With MyelofibrosisActive, not recruiting
Galecto Biotech ABIndustry
NCT04679870 · 21 participants (planned) · Start Jun 9, 2021 · Primary completion Dec 31, 2023
Drug: GB2064 · For: Myelofibrosis
Sites: Houston, Texas; Canberra, Australia; Düsseldorf, Germany · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- GB2064 (lenumlostat) shows preliminary evidence of bone marrow collagen fibrosis reduction with manageable tolerability in JAK inhibitor-refractory myelofibrosis: results from the MYLOX-1 phase IIa study.
Schlenk RF, Harrison CN, Palandri F, et al. · Haematologica 2026
Also in development for Myelofibrosis
- ElriterceptTAK-226, KER-050Phase 36 trials
Takeda · Myelodysplastic Syndromes, Myelofibrosis, Anemia
- BomedemstatMK-3543, IMG-7289Phase 35 trials
Merck & Co. · Polycythemia Vera, Essential Thrombocythemia, Thrombocythemia, Essential
- RovadicitinibTQ05105Phase 35 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Graft Versus Host Disease, Myelofibrosis, Graft-versus-host Disease
- KRT-232NavtemadlinPhase 34 trials
Kartos Therapeutics, Inc. · Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
- PelabresibDAK539, CPI-0610Phase 34 trials
Novartis · Myelofibrosis, Primary Myelofibrosis, Primary Myelofibrosis (PMF)
- BMS-986158Phase 22 trials
Bristol Myers Squibb · Myelofibrosis, Multiple Myeloma
- DISC-0974Phase 22 trials
Disc Medicine, Inc · Anemia, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (IBD); Anemia
- amsulostatPXS-5505Phase 21 trial
Syntara · Myelofibrosis, Primary Myelofibrosis (PMF), Post- Essential Thrombocythemia Myelofibrosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.